logo
Twitter
Discord
Email
logo
Dr. Reddy's Laboratories Limited

Dr. Reddy's Laboratories Limited

NYSE•RDY
CEO: Mr. Gunupati Venkateswara Prasad B.E.
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Listing Date: 2001-04-11
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
Contact Information
8-2-337, Road No. 3, Banjara Hills, Hyderabad, 500034, India
91-40-4900-2900
www.drreddys.com
Market Cap
$10.75B
P/E (TTM)
16.7
94.6
Dividend Yield
0.7%
52W High
$16.17
52W Low
$12.26
52W Range
17%
Rank27Top 14.4%
5.4
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Average • 5.4 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2016-2025

Financial Dashboard

Q2 2026 Data

Revenue

$1.01B+9.84%
4-Quarter Trend

EPS

$0.20+14.67%
4-Quarter Trend

FCF

$62.31M+286.50%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Total Revenue Growth Total revenues reached Rs. 325,535 M, marking a 16.6% increase over the prior year period, driven by volume.
Generics Segment Leads Global Generics revenue grew 18% to Rs. 289,552 M, supported by strong performance across North America and Europe.
Strategic Acquisitions Complete Completed Haleon NRT acquisition for up to Rs. 56,121 M and Nestlé India deal, strengthening OTC portfolio reach.
Operating Cash Flow Up Cash flow from operating activities increased to Rs. 46,428 M, supported by lower working capital requirements during the year.

Risk Factors

Margin Compression Intensifies Net profit margin fell to 17.6% from 19.9% due to 22% rise in SG&A expenses and increased R&D spending.
Significant Asset Impairment Recorded impairment charge of Rs. 1,693 M on non-current assets, a substantial increase from Rs. 3 M recorded previously.
Regulatory and Litigation Exposure Facing ongoing US antitrust MDL 2724 and Canadian competition act class actions, requiring vigorous defense against uncertain liabilities.
Geopolitical Supply Chain Risk Ongoing conflicts in Russia/Ukraine and Middle East create uncertainty for supply chains, logistics costs, and operational stability.

Outlook

Future Growth Strategy Pillars Future growth strategy centers on three pillars: market leadership, operational excellence, and patient-focused innovation across segments.
Capital Expansion Planned Committed Rs. 14,567 M for capital expenditures, primarily enhancing injectable facility capacity and infrastructure in India.
NRT Integration Timeline Integration of acquired Haleon NRT business operations is phased, expected to complete gradually through February 2026 across all markets.
ESG Commitment Underpins Strategy is underpinned by sustainability goals, focusing on environmental stewardship, product accessibility, and enhancing stakeholder trust.

Peer Comparison

Revenue (TTM)

Viatris Inc.VTRS
$14.12B
-6.1%
Baxter International Inc.BAX
$11.02B
-6.3%
Encompass Health CorporationEHC
$5.80B
+11.1%

Gross Margin (Latest Quarter)

Neurocrine Biosciences, Inc.NBIX
98.2%
-0.5pp
Exelixis, Inc.EXEL
96.9%
+0.1pp
BioMarin Pharmaceutical Inc.BMRN
82.0%
+7.2pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
EXAS$19.45B-19.6-40.4%43.0%
VTRS$14.81B-4.1-22.7%38.8%
RVTY$13.35B55.63.2%27.8%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
0.7%
Moderate Growth
4Q Net Income CAGR
-0.5%
Stable Profitability
Cash Flow Stability
100%
Strong Cash Flow

Research & Insights

Next earnings:Jan 22, 2026
|
EPS:$0.16
|
Revenue:$935.20M
Reports
All Years
  • Form 20-F - FY 2025

    Period End: Mar 31, 2025|Filed: Jun 6, 2025|
    Revenue: $3.85B+16.6%
    |
    EPS: $0.80+1.6%
    Beat
  • Form 20-F - FY 2024

    Period End: Mar 31, 2024|Filed: Jun 12, 2024|
    Revenue: $3.37B+13.5%
    |
    EPS: $0.81+23.0%
    Beat
  • Form 20-F - FY 2023

    Period End: Mar 31, 2023|Filed: Jun 13, 2023|
    Revenue: $3.06B+14.7%
    |
    EPS: $0.67+91.0%
    Beat
  • Form 20-F - FY 2022

    Period End: Mar 31, 2022|Filed: Jun 27, 2022|
    Revenue: $2.87B+8288.8%
    |
    EPS: $0.38+36.7%
    Miss
  • Form 20-F - FY 2021

    Period End: Mar 31, 2021|Filed: Jun 30, 2021|
    Revenue: $2.55B-98.5%
    |
    EPS: $0.28-82.3%
    Miss